0001209191-23-017636.txt : 20230309
0001209191-23-017636.hdr.sgml : 20230309
20230309182159
ACCESSION NUMBER: 0001209191-23-017636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230307
FILED AS OF DATE: 20230309
DATE AS OF CHANGE: 20230309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PIMSTONE SIMON N.
CENTRAL INDEX KEY: 0001620084
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36687
FILM NUMBER: 23721083
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G4W8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001582313
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980661854
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
BUSINESS PHONE: (604) 484-3300
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-07
0
0001582313
Xenon Pharmaceuticals Inc.
XENE
0001620084
PIMSTONE SIMON N.
200 - 3650 GILMORE WAY
BURNABY
A1
V5G 4W8
BRITISH COLUMBIA, CANADA
1
0
0
0
Common Shares
2023-03-07
4
M
0
41152
2.68
A
47152
D
Common Shares
2023-03-07
4
F
0
2160
37.13
D
44992
D
Common Shares
2023-03-07
4
S
0
10990
37.01
D
34002
D
Common Shares
2023-03-07
4
M
0
30864
2.59
A
64866
D
Common Shares
2023-03-07
4
F
0
1618
37.13
D
63248
D
Common Shares
2023-03-07
4
S
0
8242
36.94
D
55006
D
Stock Option (Right to Buy)
2.68
2023-03-07
4
M
0
41152
0.00
D
2023-03-10
Common Shares
41152
0
D
Stock Option (Right to Buy)
2.59
2023-03-07
4
M
0
30864
0.00
D
2023-03-09
Common Shares
30864
0
D
The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares subject to the options are fully vested and exercisable.
Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.
/s/ Cassandra Robinson, Power of Attorney
2023-03-09